Unveiling the therapeutic potential of silibinin in head and neck squamous cell carcinoma via network pharmacology
8.5
来源：
Nature
关键字：
mRNA
发布时间：
2025-11-20 23:43
摘要：
This study investigates the therapeutic potential of silibinin in head and neck squamous cell carcinoma (HNSCC) using network pharmacology. It identifies key targets such as MMP13, SLCO1B1, and SLCO1B3, suggesting that silibinin may inhibit HNSCC progression via the interleukin-17 signaling pathway. The research highlights silibinin's promise as an anticancer agent, supported by molecular docking studies that confirm its strong binding affinity to critical targets.
原文：
查看原文
价值分投票
评分标准
新闻价值分采用0-10分制，综合考虑新闻的真实性、重要性、时效性、影响力等多个维度。
评分越高，表示该新闻的价值越大，越值得关注。
价值维度分析
domain_focus
1.0分+1.0分
business_impact
0.5分+0.5分
scientific_rigor
1.5分+1.5分
timeliness_innovation
1.5分+1.5分
investment_perspective
2.5分+2.5分
market_value_relevance
1.0分+1.0分
team_institution_background
0.5分+0.5分
technical_barrier_competition
1.0分+1.0分
关键证据
Silibinin may inhibit HNSCC progression through modulation of the interleukin-17 signaling pathway.
Molecular docking confirmed strong binding affinity between silibinin and key targets.
The study identifies MMP13, SLCO1B1, and SLCO1B3 as hub genes in silibinin-treated HNSCC.
真实性检查
否
AI评分总结
This study investigates the therapeutic potential of silibinin in head and neck squamous cell carcinoma (HNSCC) using network pharmacology. It identifies key targets such as MMP13, SLCO1B1, and SLCO1B3, suggesting that silibinin may inhibit HNSCC progression via the interleukin-17 signaling pathway. The research highlights silibinin's promise as an anticancer agent, supported by molecular docking studies that confirm its strong binding affinity to critical targets.